Investigating the secondary interactions of packing materials for size-exclusion chromatography of therapeutic proteins.

Size exclusion chromatography has become an essential tool for the protein therapeutics industry. Conceptually, it is a simple form of chromatography that is driven by entropy and sieving effects. An ideal size exclusion column would exhibit no adsorptive interactions between its internal surfaces and the solutes being analysed, but that is not easily achieved.

ICAM-1 targeted catalase encapsulated PLGA-b-PEG nanoparticles against vascular oxidative stress.

Targeted delivery of therapeutics is the favourable idea, whereas it is possible to distribute the therapeutically active drug molecule only to the site of action. For this purpose, in this study, catalase encapsulated poly(D,L-lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-b-PEG) nanoparticles were developed and an endothelial target molecule (anti-ICAM-1) was conjugated to this carrier system in order to decrease the oxidative stress level in the target site. According to the enzymatic activity results, initial catalase activity of nanoparticles was increased from 27.

Designing of dynamic polyethyleneimine (PEI) brushes on polyurethane (PU) ureteral stents to prevent infections.

Permanent antibacterial coatings have been developed by brush-like polyethyleneimine (PEI) on polyurethane (PU) ureteral stents since bacterial adhesion and biofilm formation with the following encrustation on stent surface limit their long term usage. In order to control or prevent bacterial infections; PEI chains with two different molecular weights (Mn: 1800 or 60,000 Da) were covalently attached on the polyurethane (PU) surface by "grafting to" approach to obtain a brush-like structure. Then, PEI brushes were alkylated with bromohexane to enhance the disruption of bacterial membranes with increasing polycationic character.

Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils.

Alzheimer's disease (AD) is an irreversible and progressive neurodegenerative disease that is caused by the irreversible loss of neurons in the hippocampus and cortex regions of the brain. Although the molecular mechanism of the disease is still unclear, the deposition of the amyloid beta proteins (senile plaques) in the extracellular synaptic spaces of the neocortex is suggested to play a major role in progress of AD. The increased activity of monoamine oxidase-B (MAO-B) in AD brains was suggested to cause oxidative damage, and MAO-B inhibitors have been reported to inhibit the neuronal degeneration.